Barclays Upgrades Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) to “Strong Sell”

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) was upgraded by equities researchers at Barclays to a “strong sell” rating in a report released on Tuesday, Zacks.com reports.

Separately, Royal Bank of Canada upgraded Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

Shares of RCDTF opened at $52.25 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. Recordati Industria Chimica e Farmaceutica has a one year low of $52.25 and a one year high of $52.25. The business has a fifty day moving average of $52.25 and a 200 day moving average of $51.87.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.70 EPS for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The company had revenue of $622.00 million during the quarter.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.